We are live on ! Find out more
ONTXW

Onconova Therapeutics, Inc. Warrants
ONTXW

Delisted

ONTXW was delisted on the 23rd of July, 2021.

Back to rankings

6 hedge funds and large institutions have $1.5M invested in Onconova Therapeutics, Inc. Warrants in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding

Funds holding: 5 → 6 (+1)

17% more capital invested

Capital invested by funds: $1.29M → $1.5M (+$215K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.07K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$28.9K

ONTXW Hedge Fund Activity: Q1 2017 in Review

6 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Onconova Therapeutics, Inc. Warrants (ONTXW) for Q1 2017, worth a combined $1.5M — up 17% from $1.29M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ONTXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $1.07K. The largest seller was Sabby Management, cutting an estimated $28.9K.

  • 6 institutional investors held Onconova Therapeutics, Inc. Warrants (ONTXW) as of Q1 2017, up from 5 in Q4 2016.
  • Funds reported $1.5M of Onconova Therapeutics, Inc. Warrants stock for Q1 2017, up 17% quarter-over-quarter.
  • 1 fund opened new Onconova Therapeutics, Inc. Warrants positions in Q1 2017 and 0 closed out, a net change of +1 holder.
  • The largest Onconova Therapeutics, Inc. Warrants buyer in Q1 2017 was UBS Group, an estimated $1.07K added.
  • The largest Onconova Therapeutics, Inc. Warrants seller in Q1 2017 was Sabby Management, an estimated $28.9K sold.

Based on aggregated 13F filings for Q1 2017.